Blue Water Vaccines to develop oral chlamydia vaccine
Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.
Archives for November 22, 2022
Long-COVID personalized medicine enters Phase 2 trial
GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.